Commercial vs autologous fibrin – handling from material point of view

Arita Dubņika, Karīna Egle, Ingus Skadiņš, Ilze Šalma

Research output: Contribution to conferenceAbstractpeer-review


Platelet-rich fibrin (PRF) is an autologous material derived from a patient blood with a high concentration of platelets and leukocytes. It contains high concentrations of growth factors and biologically active substances that play an important role in providing hemostasis and bone healing. PRF is used in different fields of medicine, including dentistry, oral and maxillofacial surgery. On the other hand commercially available fibrin glues take advantage of a simplified method for fibrinogen activation, bypassing the clotting cascade. Samples were prepared from donor blood (ethics commissions approval was obtained) and commercial thrombin, fibrinogen and CaCl2. Samples were compared by gel fraction, coagulation time and antibacterial drug release. For drug release Vancomycin hydrochloride and poly (lactic-co-glycolic acid) (PLGA) microcapsules were used as drug carriers. For the preparation of A-fibrin matrices, centrifugation for a shorter period of time results in a small amount of PRF. In turn, longer centrifugation promotes clot formation. As for K-fibrin matrices, thrombin should first be mixed with 40 mM CaCl2 solution and then with fibrinogen to obtain a homogeneous mass. A-fibrin matrice have longer coagulation time (30-40min) than commercial ones (2-3min). The gel fraction of K-fibrin matrices is 84.01 ± 0.54 %, which is higher than for A-fibrin matrices (65.14 ± 0.60 %). In the first hours, the maximum concentration of vancomycin was observed, which were higher for A-fibrin matrices (7,23 µg/mL) than for K-fibrin matrices (2,34 µg/mL). Furthermore, K-fibrin matrices inhibit the release of vancomycin in both microcapsule and free vancomycin form. It can be concluded that both of the materials have their pros and cons and their use  should be assessed according to the application and patient needs.Acknowledgment: The authors acknowledge financial support from the Latvian Council of Science research project No. lzp-2020/1-0054 “Development of antibacterial autologous fibrin matrices in maxillofacial surgery (MATRI-X)”.
Original languageEnglish
Publication statusPublished - 24 Mar 2021
EventRSU Research week 2021: Knowledge for Use in Practice - Rīga, Latvia
Duration: 24 Mar 202126 Mar 2021


ConferenceRSU Research week 2021: Knowledge for Use in Practice
Abbreviated titleRW2021
Internet address

Field of Science*

  • 2.5 Materials engineering

Publication Type*

  • 3.4. Other publications in conference proceedings (including local)


Dive into the research topics of 'Commercial vs autologous fibrin – handling from material point of view'. Together they form a unique fingerprint.

Cite this